Transdermal drug delivery system

A technology of a transdermal drug delivery system and drug storehouse, which is applied in the fields of cardiovascular system diseases, antipyretics, drug combinations, etc., can solve the problems of complex use process, difficult manufacturing and high price

Inactive Publication Date: 2014-07-23
JIANGSU KANGBEIDE PHARMA
View PDF9 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although people have developed an active transdermal drug delivery system later, the active transdermal drug delivery system is often expensive, difficult to manufacture, complicated to use, and too expensive to be widely used.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal drug delivery system
  • Transdermal drug delivery system
  • Transdermal drug delivery system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Each component was weighed according to the weight of each component of the drug storage layer and the adhesive layer in Example 1 in Table 1. After the components of the weighed drug storage layer are fully mixed and homogenized, the mixed colloid is coated on the backing layer material with a thickness of 0.65mm, and dried at 40°C in the dark for 2 hours and cooled to room temperature for later use; the weighed paste After the components of the layer are fully mixed and homogeneous, the mixed colloid is coated on the anti-adhesive protective layer material with a thickness of 0.30mm, and dried at 40°C in the dark for 2 hours and cooled to room temperature for later use; the two parts of the adhesive layer prepared above Composite with the drug storehouse layer and cut into 2.5cm by die 2 Specification embodiment 1 transdermal patch, with aluminum-plastic film airtight packaging, keep away from light for subsequent use.

Embodiment 2

[0041] Each component was weighed according to the weight of each component of the drug storage layer and the adhesive layer in Example 2 in Table 1. After the components of the weighed drug storage layer are fully mixed and homogenized, the mixed colloid is coated on the backing layer material with a thickness of 0.45mm, dried at 60°C for 2 hours and cooled to room temperature for later use; After the components are fully mixed and homogenized, the mixed colloid is coated on the anti-adhesive protective layer material with a thickness of 0.20mm, and dried at 60°C for 2 hours and cooled to room temperature for later use; The compound is punched and cut into 2.5cm by the mold 2 Specification Example 2 Transdermal patch, sealed and packaged with aluminum-plastic film, protected from light and stored for later use.

Embodiment 3

[0043] Each component was weighed according to the weight of each component of the drug storage layer and the adhesive layer in Example 3 in Table 1. After the components of the weighed drug storage layer are fully mixed and homogenized, the mixed colloid is coated on the backing layer material with a thickness of 0.70mm, dried at 60°C for 2 hours and cooled to room temperature for later use; After the components are fully mixed and homogenized, the mixed colloid is coated on the anti-adhesive protective layer material with a thickness of 0.20mm, and dried at 60°C for 2 hours and cooled to room temperature for later use; The compound is punched and cut into 2.5cm by the mold 2 Specification Example 3 The transdermal patch is sealed and packaged with aluminum-plastic film and stored away from light for subsequent use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a transdermal drug delivery system having a structure with two layers namely a drug storage layer and a sticking layer. The drug is stored in the drug storage layer in an over-saturated state. The matrix materials of the drug storage layer and the sticking layer are chosen from polyacrylate, polysiloxane and polyisobutylene, and are not the same material at the same time. The transdermal drug delivery system can realize the constant drug releasing.

Description

technical field [0001] The invention relates to a transdermal drug delivery system, in particular to a transdermal drug delivery system with a drug reservoir layer and an adhesive layer. Background technique [0002] In the early passive transdermal drug delivery system, the drug used the concentration gradient as the main driving force to transport the drug to the human skin and body. The drug is dissolved in the so-called drug reservoir layer or matrix layer. In transdermal patches having both an adhesive layer and a drug reservoir layer, the adhesive layer can generally also contain a small amount of drug. However, after such a patch is applied to human skin, the drug in the patch will gradually decrease with the prolongation of its use time, and its concentration gradient will show obvious changes, and the drug delivery rate will slow down, making it difficult to achieve constant drug delivery. the goal of. [0003] Although people have developed an active transdermal ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K47/32A61K47/34A61K31/4168A61K31/485A61K31/439A61K31/27A61P9/12A61P29/00
Inventor 王树明潘悦罗传涛丁忠义
Owner JIANGSU KANGBEIDE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products